Therefore, we treated CRC cells with the STAT3 pathway inhibitor Stattic, ERK/MAPK pathway inhibitor PD98059, TGF-β1 receptor antagonist SB431542, Wnt/β-catenin pathway inhibitor XAV-939 to measure the change of expression of MYC. This evidence concerns the gene STAT3 and colorectal carcinoma.